MAZE logo

MAZE
Maze Therapeutics Inc.

127
Mkt Cap
$1.44B
Volume
200,405.00
52W High
$53.65
52W Low
$6.71
PE Ratio
-10.20
MAZE Fundamentals
Price
$27.88
Prev Close
$29.00
Open
$28.85
50D MA
$44.10
Beta
0.96
Avg. Volume
1.16M
EPS (Annual)
-$2.66
P/B
4.03
Rev/Employee
$0.00
$1,725.36
Loading...
Loading...
News
all
press releases
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
Key PointsChief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026...
Nasdaq News: Markets·3d ago
News Placeholder
More News
News Placeholder
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 2,500 Shares of Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 2,500 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total value of $73,600.00. Following the completion of the transaction...
MarketBeat·5d ago
News Placeholder
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $29.46, for a total value of $441,900.00. Following the sale, the chief marketing...
MarketBeat·5d ago
News Placeholder
JPMorgan Chase & Co. Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $58.00
JPMorgan Chase & Co. boosted their price objective on Maze Therapeutics from $52.00 to $58.00 and gave the company an "overweight" rating in a research report on Tuesday...
MarketBeat·7d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen raised shares of Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·10d ago
News Placeholder
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE)
The heavy selling pressure might have exhausted for Maze Therapeutics, Inc. (MAZE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·11d ago
News Placeholder
Q1 EPS Forecast for Maze Therapeutics Raised by Analyst
Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Analysts at HC Wainwright lifted their Q1 2026 EPS estimates for Maze Therapeutics in a research note issued to investors on Wednesday, March...
MarketBeat·11d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.5% Following Earnings Beat
Maze Therapeutics (NASDAQ:MAZE) Trading 5.5% Higher Following Earnings Beat...
MarketBeat·12d ago
News Placeholder
Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease
Maze Therapeutics (NASDAQ:MAZE) outlined positive Phase II results from its open-label HORIZON study evaluating MZE829 in patients with APOL1-mediated kidney disease (AMKD), highlighting reductions...
MarketBeat·13d ago
News Placeholder
Maze Insider Reports $736K Sale. Here's What Investors Should Know as Stock Plunges 33%
Key PointsAn executive at Maze Therapeutics reported selling 15,000 shares on March 20, 2026, yielding a transaction value of $736,000 at around $49.10 per share...
Nasdaq News: Markets·13d ago
<
1
2
...
>

Latest MAZE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.